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on Outcomes of Liver Transplant
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Visual Abstract
IMPORTANCE Ischemic cold storage (ICS) of livers for transplant is associated with serious

Invited Commentary

posttransplant complications and underuse of liver allografts.
Supplemental content
OBJECTIVE To determine whether portable normothermic machine perfusion preservation

of livers obtained from deceased donors using the Organ Care System (OCS) Liver
ameliorates early allograft dysfunction (EAD) and ischemic biliary complications (IBCs).
DESIGN, SETTING, AND PARTICIPANTS This multicenter randomized clinical trial (International
Randomized Trial to Evaluate the Effectiveness of the Portable Organ Care System Liver for
Preserving and Assessing Donor Livers for Transplantation) was conducted between
November 2016 and October 2019 at 20 US liver transplant programs. The trial compared
outcomes for 300 recipients of livers preserved using either OCS (n = 153) or ICS (n = 147).
Participants were actively listed for liver transplant on the United Network of Organ Sharing
national waiting list.
INTERVENTIONS Transplants were performed for recipients randomly assigned to receive
donor livers preserved by either conventional ICS or the OCS Liver initiated at the donor
hospital.
MAIN OUTCOMES AND MEASURES The primary effectiveness end point was incidence of EAD.
Secondary end points included OCS Liver ex vivo assessment capability of donor allografts,
extent of reperfusion syndrome, incidence of IBC at 6 and 12 months, and overall recipient
survival after transplant. The primary safety end point was the number of liver graft–related
severe adverse events within 30 days after transplant.
RESULTS Of 293 patients in the per-protocol population, the primary analysis population for
effectiveness, 151 were in the OCS Liver group (mean [SD] age, 57.1 [10.3] years; 102 [67%]
men), and 142 were in the ICS group (mean SD age, 58.6 [10.0] years; 100 [68%] men).
The primary effectiveness end point was met by a significant decrease in EAD (27 of 150
[18%] vs 44 of 141 [31%]; P = .01). The OCS Liver preserved livers had significant reduction in
histopathologic evidence of ischemia-reperfusion injury after reperfusion (eg, less moderate
to severe lobular inflammation: 9 of 150 [6%] for OCS Liver vs 18 of 141 [13%] for ICS;
P = .004). The OCS Liver resulted in significantly higher use of livers from donors after
cardiac death (28 of 55 [51%] for the OCS Liver vs 13 of 51 [26%] for ICS; P = .007).
The OCS Liver was also associated with significant reduction in incidence of IBC 6 months
(1.3% vs 8.5%; P = .02) and 12 months (2.6% vs 9.9%; P = .02) after transplant.
CONCLUSIONS AND RELEVANCE This multicenter randomized clinical trial provides the first
indication, to our knowledge, that normothermic machine perfusion preservation of
deceased donor livers reduces both posttransplant EAD and IBC. Use of the OCS Liver also
resulted in increased use of livers from donors after cardiac death. Together these findings
indicate that OCS Liver preservation is associated with superior posttransplant outcomes
and increased donor liver use.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02522871
JAMA Surg. doi:10.1001/jamasurg.2021.6781
Published online January 5, 2022.

Author Affiliations: Author
affiliations are listed at the end of this
article.
Corresponding Author: James F.
Markmann, MD, PhD, Massachusetts
General Hospital, 55 Fruit St,
WHT 517, Boston, MA 02114-2696
(jmarkmann@partners.org).

(Reprinted) E1

Downloaded From: https://jamanetwork.com/ by a Henry Ford Health System User on 02/17/2022

Research Original Investigation

Impact of Portable Normothermic Blood-Based Machine Perfusion on Outcomes of Liver Transplant

L

iver transplant provides lifesaving treatment for patients with end-stage liver disease. An inadequate supply
of suitable donor organs has resulted in prolonged waiting times and high waiting list mortality rates.1,2 Historically,
liver preservation has relied almost exclusively on ischemic
cold storage (ICS).3,4 However, ICS subjects liver allografts to
ischemic injury and progressive organ deterioration, even at
4 °C.5 In addition, ICS precludes ex vivo optimization or assessment of liver function, leaving the cumulative effects of
donor quality, preservation and reperfusion injury to be revealed only after implantation.6-8 The inherent uncertainties
of livers preserved by ICS foster conservatism by transplant clinicians when considering donor organ quality, ultimately leading to underuse of available donor livers for transplant. The
organs from donors with advanced age, multiple comorbidities, or donation after circulatory death (DCD) status are frequently declined for transplant owing to the clinician’s concern for increased risk of early allograft dysfunction (EAD),
primary nonfunction, or serious chronic complications, such
as ischemic biliary complications (IBCs).9,10
Historically, advances in organ preservation have been
linked to improved posttransplant outcomes and improved donor organ use. The concept of normothermic blood-based liver
perfusion was developed to overcome the limitations of ICS.11-16
The multicenter International Randomized Trial to Evaluate the Effectiveness of the Portable Organ Care System (OCS)
Liver for Preserving and Assessing Donor Livers for Transplantation (the PROTECT trial) is the first US randomized clinical
trial for liver perfusion and was designed to overcome the limitations of ICS, limiting the period of ischemia and providing
physiologic assessment of liver graft function. The PROTECT
trial prespecified donor characteristics from donation after
brainstem death (DBD) and DCD donors that are known to be
more vulnerable to ICS associated damage.

Methods
Study Design
The PROTECT trial, a pivotal multicenter randomized clinical
trial, compared posttransplant outcomes for recipients who received donor livers preserved using ICS or the OCS Liver (trial
protocol in Supplement 1). Following initial acceptance of a donor liver for transplant, recipients were randomized 1:1 to the
OCS or ICS control group through the Interactive Web Response System. The donor liver was procured at the donor site
and was preserved according to randomization. All livers in the
OCS Liver group were initiated on the OCS Liver device at the
donor hospital. Screen failures due to the identification of intraoperative exclusion criteria in otherwise clinically suitable
livers resulted in the recipient undergoing a transplant outside of the trial using a liver processed through the standard
of care, ICS. When donor livers were deemed unsuitable for
transplant during intraoperative physical assessment, recipients remained eligible but were treated as a new patient and
rerandomized to a group at their subsequent donor offer acceptance. This practice avoided potential bias of knowing the
randomization assignment on the clinical decision of donor orE2

Key Points
Question Can oxygenated portable normothermic perfusion of
deceased donor livers for transplant improve outcomes compared
with the current standard of care using ischemic cold storage?
Findings In this multicenter randomized clinical trial of 300
recipients of liver transplants with the donor liver preserved by
either normothermic perfusion or conventional ischemic cold
storage, normothermic machine perfusion resulted in decreased
early liver graft injury and ischemic biliary complications and
greater organ utilization.
Meaning In this study, portable normothermic oxygenated
machine perfusion of donor liver grafts resulted in improved
outcomes after liver transplant and in more livers being
transplanted.

gan acceptance (eFigure 1 in Supplement 2). The trial targeted major academic liver transplant centers and was conducted in accordance with the Humanitarian Good Clinical
Practice Guidelines, with each site obtaining the appropriate
institutional review board approval. This trial also followed the
Consolidated Standards of Reporting Trials (CONSORT)
reporting guideline. All participants gave written informed
consent that was obtained in a manner consistent with the
Common Rule requirements. No one received compensation
or was offered any incentive for participating in this study.

Participants
The PROTECT trial objective was to compare the safety and
the effectiveness of the OCS Liver vs ICS for donors with at
least 1 of the following characteristics: (1) 40 years of age or
older; (2) expected total cross-clamp/cold ischemic time of 6
or more hours; (3) DCD donors if 55 years or younger; or (4)
macrosteatotic livers (≤40%). Donor liver exclusion criteria included living donors, split livers, livers requiring accessory vessel reconstruction, or moderate to severe traumatic liver injury. Recipient exclusion criteria included younger than 18
years, acute or fulminant liver failure, prior solid organ or bone
marrow transplant, chronic kidney failure, multiorgan transplant, ventilator dependence, or hemodynamic compromise.

The OCS Liver
The OCS Liver consisted of an integrated system of 3 components: the OCS Liver console, OCS Liver perfusion set, and OCS
bile salt solution for infusion (Figure 1A). The OCS Liver maintains the donor liver in a nonischemic, metabolically active
state by perfusing both portal venous and hepatic arterial circulations with a warm, oxygenated and nutrient-enriched,
blood-based perfusate. The OCS Liver is capable of delivering
high-pressure pulsatile perfusion to the hepatic arterial circulation while simultaneously delivering low-pressure, highflow perfusion to the portal circulation with a single perfusion pump, giving the user full control over the perfusion
parameters (eFigure 2 in Supplement 2).

Procedures
After organ acceptance, potential liver recipients who had provided informed consent for participating in the PROTECT trial
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Figure 1. Organ Care System (OCS) Liver Components
A OCS Liver components

OCS Liver console
B

OCS Liver perfusion module

OCS Liver bile salts

controlled for focus and scanning artifacts and entered into a
21 CFR Part 11 compliant imaging database for prospective
scoring (treatment group and donor organ subtype were not
available to the reviewing pathologist). In total, 42 histopathologic criteria were electronically recorded in the database,
which included comprehensive semiquantitative assessment of severity and composition of portal, lobular, and any
other notable features. We used CD31 staining to assess the
integrity of the endothelium lining. At the completion of the
study, all histopathologic scoring was extracted and analyzed
using R, version 3.6.3 (R Foundation for Statistical Computing) for graphical and statistical data review, summary, and
presentation.

Lactate levels during OCS Liver perfusion

Outcomes
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A, The OCS Liver is primed with buffered electrolyte solution, albumin, 4 to 5
units of packed red blood cells, and broad-spectrum antibiotics. Perfusion
gradually increased to 2.0 to 2.5 L total flow, and temperature was set at 34 °C.
The perfusate was supplemented with continuous infusion of a nutrient
solution of 4% amino acids and 10% dextrose, supplemented with insulin and
multivitamins. Liver perfusion hemodynamic parameters were monitored
continuously and recorded throughout preservation. Serial blood gases and
lactate levels were measured throughout preservation, and changes in lactate
level were used to measure adequacy of perfusion. B, Donor livers that were
transplanted vs clinically turned down based on OCS Liver assessment of lactate
levels. Error bars represent SD.

were randomized to OCS Liver or to ICS preservation of the donor liver before the recovery team departed for organ retrieval. During organ recovery, once donor livers were examined and accepted for transplant and for inclusion in the
PROTECT trial, preservation followed the randomization assignment. For the OCS Liver instrumentation, the hepatic artery and portal vein were cannulated for inflow, and the
suprahepatic cava for outflow; the common bile duct was
cannulated for bile collection and quantitation. Typespecific or O Rh-negative blood was sourced from banked irradiated, leukocyte-depleted packed red blood cells.
Formalin-fixed biopsy material was received by the central laboratory, paraffin embedded, and sectioned at 4 μm prior
to routine staining with both hematoxylin-eosin and CD31
(mouse monoclonal, M0823; Dako) immunostaining protocols. Sections were assessed for sectioning and staining quality before being converted to high-resolution (40×; 0.116 μm/
pixel) whole-slide imagery using a Zeiss AxioScan.Z1 automated
scanning system. Resultant whole-scan images were quality

The primary effectiveness end point was the incidence of
EAD,10 defined as the presence of 1 or more of the following:
aspartate aminotransferase level higher than 2000 IU/L (to
convert to microkatals per liter, multiply by 0.0167) within the
first 7 postoperative days; bilirubin 10 mg/dL or higher (to convert to micromoles per liter, multiply by 17.104) on postoperative day 7; international normalized ratio of 1.6 or higher on
postoperative day 7; or graft primary nonfunction within the
first 7 days, defined as irreversible graft dysfunction leading
to recipient death or emergency retransplant, in the absence
of immunologic or surgical causes.
The secondary effectiveness and other critical clinical
end points included the ability of the OCS Liver to monitor
donor liver function throughout preservation; patient
survival at day 30 or at initial hospital discharge if longer
than 30 days; incidence of IBC defined as nonanastomotic
ischemic strictures or bile leaks, confirmed with an endoscopic retrograde cholangiopancreatography or magnetic
resonance cholangiopancreatography radiologic examination and blindly adjudicated by a 3-member independent
clinical events committee; extent of reperfusion syndrome
after transplant assessed by recipient’s lactate levels
approximately 120 minutes after reperfusion in the recipient; and histologic assessment of the donor liver after transplant compared with baseline histologic specimen obtained
before retrieval from the donor. All histopathologic evaluations were assessed using a blinded, independent core
laboratory with extensive experience in liver transplant
pathology.
The primary safety end point was the mean number of
liver graft–related severe adverse events (LGRSAEs) per patient within the initial 30 days after liver transplant. The LGRSAEs were predefined as a primary nonfunctioning graft, IBCs,
hepatic vascular complications, or liver graft infection.

Statistical Analysis
The primary analysis population for effectiveness was the perprotocol population, consisting of all randomized recipients
who received a donor liver that underwent the complete preservation procedure as per randomization assignment and had
no major protocol violations. Safety was analyzed based on the
as-treated population, consisting of all patients with a liver
allograft. The modified intention-to-treat population con-
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sisted of all randomized patients who underwent a transplant in the PROTECT trial.
The PROTECT trial was designed to test for both noninferiority and superiority if noninferiority was met. The primary
effectiveness end point was analyzed by calculating the sample
proportion of patients meeting the primary effectiveness
end point, as well as an exact (Clopper-Pearson) 95% CI for the
corresponding population proportion. The 95% upper bound
of the exact unconditional 1-sided CI based on the FarringtonManning score was calculated for the difference between the
2 population proportions (OCS − ICS). An upper confidence
limit lower than δ = 0.075 would result in rejection of the null
hypothesis in favor of the alternative hypothesis and the demonstration of noninferiority of OCS to ICS for the primary effectiveness end point. In the event noninferiority was demonstrated, the Fisher exact test (2-sided) was used to assess
for superiority. The secondary end points were analyzed in a
manner analogous to the primary effectiveness end point.
The safety end point was analyzed by treatment group
using descriptive statistics. For the mean number of LGRSAEs, the hypothesis was that the OCS Liver treatment was
noninferior to the standard of care treatment, with a noninferiority margin of 1.00. The safety end point was analyzed
using a 1-sided, 2-sample t test with an α level of .05. Statistical analyses were conducted using SAS Studio, version 9.4
(SAS Institute Inc).

Results
Between November 2016 and October 2019, a total of 429
patients provided informed consent to participate in the
PROTECT trial, and 300 patients were randomized and received a liver allograft (153 in the OCS Liver group and 147 in
the ICS group) (Figure 2). One recipient who was to receive an
ICS-perfused liver died in the operating room during surgery
prior to initiating organ implantation. There were 2 treatment crossovers owing to reallocation after randomization, 1
in the OCS Liver group and 1 in the ICS group. The as-treated
population consisted of 299 patients (153 in the OCS Liver group
and 146 in the ICS group); 1 patient in the OCS Liver group received an allograft without having been randomized, leaving
the modified intention-to-treat population consisting of 298
patients (152 in the OCS Liver group and 146 in the ICS group).
After we removed the major protocol violations, the perprotocol population consisted of 293 patients (151 in the OCS
Liver group and 142 in the ICS group). The donor demographic characteristics and risk factors were comparable between the 2 groups except for more DCD donors (28 of 151; 19%)
in the OCS Liver group (11 of 143; 8%). The mean SD age of donors was 45.9 (14.9) years in the OCS Liver group and 46.9 (15.3)
years in the ICS group. Recipient demographic characteristics and risk factors were also equivalent between the 2 groups
(Table). For the OCS Liver group, the mean (SD) age was 57.2
(10.3) years, 100 recipients (66%) were men, and 51 recipients (34%) were women. For the ICS group, the mean (SD)
age was 58.4 (10.1) years, 98 recipients (69%) were men, and
44 recipients (31%) were women.
E4

OCS Donor Liver Preservation Parameters, OCS Liver Use,
and Critical Transplant Times
Donor livers were perfused with the OCS Liver for a mean
(SD) of 276.6 (117.4) minutes and were maintained in near
physiologic condition as shown by decreasing lactate levels
from the start (mean [SD], 7.2 [3.2] mmol/L) to the end of
perfusion (mean [SD], 1.21 [1.0] mmol/L) (to convert lactate
levels to milligrams per deciliter, divide by 0.111) (eTable 1 in
Supplement 2). The use of the OCS Liver significantly
reduced the mean (SD) cold ischemia time of the donor livers
to 175.4 (43.5) minutes compared with 338.8 (91.5) minutes
for ICS (P < .001), despite the OCS Liver having significantly
longer total cross-clamp (out of body) time (mean [SD],
454.9 [133.9] vs 338.8 [91.5] minutes) (P < .001). Overall, 155
DBD and DCD donor livers were assessed using the OCS
Liver. Of those, 152 donor livers (98%) were successfully
transplanted and analyzed in the PROTECT Trial. The 3
donor livers that failed OCS Liver assessment were from
DCDs; 2 livers were rejected owing to lactate levels that continued to increase and reached higher than 10 mmol/L
despite target flow parameters (Figure 1B), and 1 liver was
rejected based on a pathologic finding of bridging fibrosis
after recovery. We analyzed the effect of preservation
modality on donor liver use for transplant from DBD and
DCD donors. In this analysis, there was no difference in the
percentage of DBD donor livers used between the OCS Liver
or ICS group (124 of 154 [80%] in the OCS Liver group vs 133
of 168 [79%] in the ICS group). However, there was a significantly higher rate of DCD donor livers used for transplant
associated with the OCS Liver compared with ICS (28 of 55
[51%] vs 13 of 51 [26%]; P = .007) (eFigure 3 in Supplement 2). The OCS Liver was readily integrated into 20 trial
centers in which all teams were trained to perform all OCS
Liver instrumentation, management, and assessment of
donor livers during the entire preservation period in the
trial. During the PROTECT trial, there were 3 minor device
issues reported by trial centers (3 of 155 devices; 2%). Two
issues were related to small plastic components in the perfusion module that did not interfere with the OCS Liver preservation or with the management of the donor livers on the
system. One of the issues occurred well before the donor
liver was retrieved prior to OCS Liver instrumentation. All 3
livers were transplanted successfully in the PROTECT Trial
and their outcomes were analyzed in the results.

Primary Effectiveness End Point
The PROTECT trial met its primary effectiveness end point
by demonstrating statistical noninferiority and superiority of
outcomes of the OCS Liver group compared with the ICS
group in both the per-protocol population and the modified
intention-to-treat analysis population. Specifically, the use
of the OCS Liver was associated with a significant decrease
in the incidence of EAD compared with ICS in the primary
analysis per-protocol population (27 of 151 [18%] vs 44 of 142
[31%]; P = .01). A similar effect was seen in the modified
intention-to-treat population (Figure 3A). This significant
reduction of EAD in the OCS group was further validated
mechanistically by histopathologic assessment of liver graft
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Figure 2. PROTECT Trial Consolidated Standards of Reporting Trials Diagram
429 Patients provided written informed consenta
37 Screen failures
22 Remained on waiting list
9 Delisted for Tx
4 Died while on waiting list for donor offer
2 Withdrew consent

476 Randomizeda

241 OCS Liver

235 Control

88 Screen failures
57 Liver rejected for treatment in donor bodyb
28 Received allograft off study
(donor ineligible or logistical issues)c
3 Rejected after assessment on OCS
Liver Systemd

88 Screen failures
73 Liver rejected for Tx in donor bodyb
15 Received allograft off study
(donor ineligible or logistical issues)c

300 Enrolled in OCS Liver PROTECT trial and
received liver allograft

142 Received control liver allograft
1 Treated in OCS Liver group
1 Died in operating room prior to treatment
4 Major protocol violations

151 Received OCS Liver allograft
1 Treated in conrol group
1 Treated without randomized allocation
1 Major protocol violation

299 As-treated and safety population
298 Modified intention-to-treat population
293 Per-protocol population

and 5 in the ICS group) owing to reallocation, donor did not progress, or
logistical reasons.

ICS indicates ischemic cold storage; OCS, Organ Care System; Tx, transplant.
a

b

Some patients had more than 1 randomization event when the prior donor
liver was unsuitable for clinical use after assessment in the body and the
subsequent donor liver offer met study criteria. Rerandomization was
performed as detailed in eFigure 1 in Supplement 2. This rerandomization
process resulted in 476 randomizations in 392 patients.
Of 130 livers (57 in the OCS Liver group and 73 in the ICS group) rejected for
transplant in donor body after randomization, 42 (18 in the OCS Liver group
and 24 in the ICS group) were rejected because the donor (after cardiac death)
did not expire within 30 minutes; 31 (9 in the OCS Liver group and 22 in the
ICS group) owing to clinical judgment at retrieval; 27 (13 in the OCS Liver group
and 14 in the ICS group) owing to steatosis; 9 (3 in the OCS Liver group and 6
in the ICS group) showed cirrhosis or fibrosis; 4 (2 in the OCS Liver group and 2
in the ICS group) showed vasculature abnormalities or disease; 3 (3 in the OCS
Liver group and 0 in the ICS group) owing to donor-recipient organ size
mismatch; 2 (2 in the OCS Liver group and 0 in the ICS group) revealed liver or
kidney malignant neoplasm during retrieval; and 12 (7 in the OCS Liver group

biopsies after reperfusion. This assessment revealed that the
OCS Liver was associated with significantly less lobular
inflammation (for moderate to severe, 9 of 150 [6%] vs 18 of
141 [13%]; P = .004), a marker of ischemia-reperfusion
injury17-19 (Figure 3B and C). By contrast, portal inflammation, a histologic marker not associated with ischemiareperfusion injury, was similar between groups (moderate to
severe, 2 of 150 [1.3%] vs 1 of 141 [0.7%]; P = .39). We exam-

c

Of 43 recipients (28 in the OCS Liver group and 15 in the ICS group) treated off
study after randomization using cold storage, 39 (24 in the OCS Liver group
and 15 in the ICS group) were because the donor liver did not meet eligibility
owing to accessory vessels, liver hematoma or required surgical vascular
repair; and 4 (4 in the OCS Liver group and 0 in the ICS group) were because of
logistic reasons, including donor family did not consent to research (Organ
Procurement Organization requirement), preretrieval liver biopsy could not be
obtained; Organ Procurement Organization delayed operating room time,
resulting in trained trial retrieval team being off call; and recipient
deterioration with renal insufficiency on day of transplant.

d

Of 3 livers from donors after cardiac death that were rejected for use after OCS
Liver assessment, 2 were rejected because of increasing lactate levels despite
maximizing OCS Liver perfusion parameters; and 1 because donor liver
preretrieval biopsy revealed extensive bridging fibrosis.

ined the clinical effect of reducing EAD by stratifying all trial
recipients outcomes by presence or absence of EAD. We
found that EAD was associated with significantly higher risk
of graft failure compared with no EAD (log-rank test
P = .003) (Figure 4A), significantly longer ICU stay (mean
[SD], 7.7 [16.9] vs 3.4 [4.8] days; P = .04) and significantly
longer overall hospital stay (mean [SD], 15.7 [19.0] vs 10.1
[7.9] days; P = .02) (Figure 4A and B).
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Table. Donor and Recipient Demographic Characteristics and Risk Factors for Transplanted Organs
and Recipients
Donors or recipients in primary analysis
per-protocol population, No. (%)

Donors or recipients in as-treated
population, No. (%)

OCS Liver

ICS

OCS Liver

ICS

151

142

153

146

Mean (SD)

45.9 (14.9)

46.9 (15.3)

45.8 (14.9)

47.0 (15.2)

Median (range)

47.5 (10.9-83.7)

45.8 (13.0-80.6)

47.3 (10.9-83.7)

46.4 (13.0-80.6)

102 (68)

91 (64)

102 (67)

93 (64)

Characteristic or risk factor
Donor
No.
Age, y

Age ≥40 y
Total cross-clamp time ≥6 h

47 (31)

54 (38)

48 (32)

56 (38)

DCD age ≤55 y

28 (19)

11 (8)

28 (18)

13 (9)

Steatotic liver >0% and ≤40%
macrosteatosis

94 (62)

86 (61)

95 (63)

86 (59)

Multiple donor characteristics

94 (62%)

85 (58)

151

142

152

146

Mean (SD)

57.2 (10.3)

58.4 (10.1)

57.1 (10.3)

58.6 (10.0)

Median (range)

59.2 (19.5-76.6)

61.4 (20.8-77.8)

59.2 (19.5-76.6)

58.2 (20.8-77.8)

Male

100 (66)

98 (69)

102 (67)

100 (68)

Female

51 (37)

44 (31)

51 (33)

46 (32)

29.7 (5.4)
[16.3-45.5]

29.5 (5.5)
[17.1-44.7]

29.7 (5.4)
[16.3-45.5]

29.5 (5.5)
[17.1-44.7]

Mean (SD)

28.4 (6.9)

28.0 (5.7)

28.4 (6.9)

28.0 (5.7)

Median (range)

29.0 (6.0-49.0)

29.0 (9.0-46.0)

29.0 (6.0-49.0)

29.0 (9.0-46.0)

Cholestatic diseases

9 (6)

8 (6)

9 (6)

8 (5)

Chronic hepatitis

26 (17)

35 (25)

27 (18)

36 (25)

Alcoholic cirrhosis

53 (35)

47 (33)

54 (35)

48 (33)

Metabolic diseases

6 (4)

6 (4)

6 (4)

6 (4)

Primary hepatic tumors

14 (9)

15 (11)

14 (9)

15 (10)

NASH

24 (16)

18 (13)

24 (16)

20 (14)

Other

19 (13)

13 (9)

19 (12)

13 (9)

Recipient
No.
Age, y

Sex

BMI, mean (SD) [range]
MELD score

Primary diagnosis

Secondary and Other Critical Clinical End Points
The OCS Liver permitted continuous monitoring and assessment of lactate levels, bile production, and hepatic artery
and portal vein pressures and flows throughout preservation
(eTable 1 in Supplement 2). Patient survival at day 30 after
transplant was 99.3% (150 of 151) for the OCS Liver group vs
99.3% (141 of 142) for the ICS group (noninferiority P < .001),
and at initial hospital discharge, patient survival was
98.7% (149 of 151) for the OCS Liver group vs 98.6% (140 of
142) for the ICS group (noninferiority P < .001). The OCS
Liver was associated with a significant decrease in ischemic
biliary complications 6 months (2 of 151 [1.3%] vs 12 of
142 [8.5%]; P = .02) and 12 months (4 of 151 [2.6%] vs 14
of 142 [9.9%]; P = .02) after transplant (Figure 3D). Reperfusion syndrome was more severe in the ICS group compared
with the OCS Liver group based on significantly higher
recipient lactate levels at approximately 120 minutes
after reperfusion (mean [SD], 3.64 [2.22] vs 4.33 [2.98]
E6

Abbreviations: BMI, body mass index
(calculated as weight in kilograms
divided by height in meters squared);
DCD, donor after cardiac death;
ICS, ischemic cold storage;
MELD, Model for End-stage Liver
Disease; NASH, nonalcoholic
steatohepatitis; OCS, Organ Care
System.

mmol/L; P = .046).20 There was no difference in the incidence of anastomotic nonischemic biliary complications
(eTable 2 in Supplement 2). Overall 12-month patient survival was 94.0% (142 of 151) for the OCS Liver group and
93.7% (133 of 142) for the ICS group (eFigure 4A and B in
Supplement 2).

Safety End Point
The PROTECT trial met its safety end point showing that the
mean (SD) number of LGRSAEs within the initial 30 days after
transplant for the OCS Liver was noninferior to ICS (mean [SD],
0.046 [0.210] per patient in the OCS Liver group vs 0.075
[0.265] per patient in the ICS group; noninferiority P < .001).
The type of LGRSAEs observed within the initial 30 days after
transplant revealed an apparent decrease for the OCS Liver vs
ICS in both IBCs (0 vs 2 events in 2 patients) and vascular
complications (8 events in 7 patients vs 11 events in 9
patients) (eTable 3 in Supplement 2).
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Figure 3. PROTECT Trial Primary Effectiveness End Point (Incidence of Early Allograft Dysfunction [EAD]), Posttransplant Pathology Assessment
(Incidence of Liver Lobular Inflammation), Posttransplant Histology Representative Specimens of Moderate to Severe Lobular Inflammation,
and PROTECT Trial Incidence of Ischemic Biliary Complications Within 12 Months After Transplant
A Incidence of EAD

50

B

Noninferiority P <.001
Superiority P =.01

Noninferiority P <.001
Superiority P =.005

P =.004
80
OCS Liver

Samples, %

Incidence of EAD, %
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Histologic specimens showing moderate to severe lobular inflammation
after transplant
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∗
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D Incidence of ischemic biliary complications in the PROTECT trial
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0
OCS Liver (N = 151)

C

Posttransplant pathology assessment: incidence of liver lobular inflammation
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15

10

5

0
OCS Liver

Control

6 mo After transplant

OCS Liver
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12 mo After transplant

A, Clopper-Pearson exact CI for a binomial percentage, with 95% 1-sided upper confidence bound based on the Farrington-Manning score statistic.
The noninferiority P values are based on the 1-sided Farrington-Manning score statistic, testing the null hypothesis that the true Organ Care System (OCS) Liver
proportion is greater than or equal to the true ischemic cold storage (ICS) proportion δ = 0.075 vs the alternative hypothesis that it is less than the true ICS
proportion plus 0.075. The superiority P values are from a 2-sided Fisher exact test, testing the null hypothesis that the true difference in proportions equals 0 vs the
alternative hypothesis that it does not equal 0. This analysis was conducted only if the null hypothesis of inferiority was rejected. Error bars represent 95% CIs.
B, The P value was determined using the χ2 test. C, Histologic specimens showing examples of severe lobular inflammation in a control ICS (left) liver after
reperfusion, with inset showing minimal portal inflammation, and an OCS Liver–treated liver (right) showing absence of lobular inflammation and minimal portal
inflammation (inset). The asterisk indicates the location of the portal tract (PT). D, Ischemic biliary complications, defined as nonanastomotic ischemic strictures or
bile leaks, confirmed with an endoscopic retrograde cholangiopancreatography or magnetic resonance cholangiopancreatography radiologic examination.

Discussion
Until the recent development of perfusion strategies,12-16,21-28
solid organ preservation had been restricted to ICS, with the
concern of resultant ischemia-reperfusion injury5,8 contributing to underuse of donor organs for transplant. The results
of this randomized clinical trial showed that portable normothermic machine perfusion, the OCS Liver, was superior to
ICS, conferring a lower incidence of EAD and IBCs in recipients of liver allografts.
Some clinicians have championed using in situ normothermic regional perfusion in the donor body prior to DCD liver

allograft retrieval.27,29 This approach has not been broadly adopted owing to the complexity and impracticality of routine
implementation during multiorgan recovery and because a period of cold storage generally follows normothermic regional
perfusion. Nasralla et al16 reported the first European randomized clinical trial of normothermic machine perfusion in 220
liver transplants and showed early significant reduction in peak
enzymes in the normothermic machine perfusion group. However, protection from IBC was not observed, and there was no
reported mechanistic explanation for the peak enzyme differences. A recent nonrandomized study used end-ischemic normothermic machine perfusion for donor livers that would have
otherwise been discarded.30 Donor livers in that trial had a me-
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Figure 4. Effect of Early Allograft Dysfunction (EAD) in the Per-Protocol Population on Graft Survival Probability and on Posttransplant
Intensive Care Unit (ICU) Stay and Overall Hospital Stay
A Graft survival probability
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dian of more than 8 hours of ICS prior to commencing normothermic machine perfusion, perhaps explaining the disappointing results that included a rate of IBC requiring retransplant of 30% among recipients of DCD grafts. These
findings further highlight the importance of portability to a
normothermic liver perfusion system, enabling initiation of
perfusion at the donor hospital to maximally reduce ICS.
In contrast to these efforts, the hypothermic oxygenated
perfusion at the end of a cold ischemic period (HOPE) protocol recently showed impressive reduction in EAD and prevention of IBC in DCD liver transplant.31 Thus, HOPE and OCS approaches may have complementary applications depending on
the clinical situation. However, cold perfusion is suboptimal
to assess the transplantability of steatotic livers and may therefore not be relevant in the assessment of organs currently being
discarded after recovery or not deemed worthy of recovery.32
The PROTECT trial was designed to overcome the significant limitations of ICS and to evaluate the clinical effect of reducing ischemic injury and providing functional assessment
of liver allografts using a portable normothermic perfusion system. The use of the OCS Liver resulted in a significant reduction in ischemic injury associated with ICS and led to superior short-term and midterm clinical outcomes, with significant
reduction of EAD and IBC through 12 months’ follow-up. The
PROTECT trial provided clear mechanistic corroboration of the
marked reduction of EAD observed in the trial based on the
significant decrease in the histologic marker of ischemiareperfusion injury, lobular inflammation, observed on histologic specimens recovered following reperfusion of the graft
in the recipient, and significant mitigation of reperfusion syndrome in the recipient after transplant in the OCS group. The
clinical importance of reducing EAD was reflected in significantly shorter ICU and hospital stays, and significant improvement in posttransplant graft survival. The PROTECT trial met
its safety end point and reported low rates of LGRSAEs.
The PROTECT trial targeted DCD donors and DBD donors
having risk factors that included older age, moderate level of
E8

steatosis, or anticipated long cross-clamp time, that portend
EAD, primary nonfunction, or IBC. Use of the OCS Liver resulted in significantly increased DCD donor use as compared
with ICS. These data suggest that the OCS Liver provided additional opportunity for ex vivo clinical optimization and assessment of the DCD liver graft, resulting in a higher proportion of DCD livers being successfully transplanted with the use
of the OCS Liver compared with ICS. These results confirm
the inherent clinical benefits of normothermic machine perfusion to provide an additional clinical quality assessment of
liver allografts. Increasing use of DCD and questionable DBD
liver allografts by demonstrating their viability and suitability for transplantation will likely be the greatest clinical benefit of ex vivo perfusion in liver transplant. The portability of
the OCS Liver will likely gain increasing importance as organ
retrieval teams travel further to recover organs with recently
adopted allocation rules that mandate broader sharing of donor livers in the US.33

Limitations
Complete blinding of the clinical teams to the preservation modality was impossible given the complex logistics involved in
the application of machine perfusion at a remote site. Therefore, the randomization step was designed to occur only after
the clinical decision of accepting the donor offer had been made
based on clinical facts about the donor and without any knowledge of the preservation modality. If for any reason, the donor liver was rejected for transplant on physical examination
during organ retrieval, the protocol prespecified that the potential recipient be rerandomized after a second donor liver
was offered and clinically accepted. This process was established to ensure that clinical decision-making was the primary driver for accepting donor liver allografts and was not
influenced by preservation modality. The balanced donor and
recipient characteristics and risk factors as well as the equivalent baseline donor liver pathology assessment validate the
robustness of this randomization process.
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Conclusions
The PROTECT trial showed superior short-term and midterm clinical outcomes and higher numbers of donor livers used

ARTICLE INFORMATION
Accepted for Publication: October 25, 2021.
Published Online: January 5, 2022.
doi:10.1001/jamasurg.2021.6781
Open Access: This is an open access article
distributed under the terms of the CC-BY License.
© 2022 Markmann JF et al. JAMA Surgery.
Author Affiliations: Massachusetts General
Hospital, Boston (Markmann, Kimura, Yeh); Henry
Ford Transplant Institute, Detroit, Michigan
(Abouljoud, Rizzari); Houston Methodist, Houston,
Texas (Ghobrial, Saharia); Virginia Commonwealth
University, Richmond (Bhati, Levy); University of
Virginia, Charlottesville (Pelletier, Agarwal); Tampa
General, Tampa, Florida (Lu); Johns Hopkins,
Baltimore, Maryland (Ottmann); UT Health Science
Center, San Antonio, Texas (Klair, Cigarroa);
University of Tennessee Health Science Center,
Memphis (Eymard, Eason); UCSF, San Francisco,
California (Roll, Syed); Emory University Hospital,
Atlanta, Georgia (Magliocca); University of
Minnesota, Minneapolis (Pruett); University of
Washington, Seattle (Reyes); The Ohio State
University, Columbus (Black, Washburn); Scripps
Clinic and Scripps Green Hospital, San Diego,
California (Marsh); University of California, San
Diego, La Jolla (Schnickel, Parekh); Montefiore
Medical Center, Bronx, New York (Kinkhabwala);
Mount Sinai Health System, New York, New York
(Florman, Moon); University of Nebraska Medical
Center, Omaha (Merani, Maskin); University of
Pittsburgh Medical Center, Pittsburgh,
Pennsylvania (Demetris); University of Texas
Southwestern Medical Center, Dallas (Vagefi,
MacConmara).
Author Contributions: Drs Markmann and
MacConmara had full access to all of the data in the
study and take responsibility for the integrity of the
data and the accuracy of the data analysis.
Concept and design: Markmann, Abouljoud,
Magliocca, Demetris, Kimura, Saharia, Agarwal,
Moon, Maskin, MacConmara.
Acquisition, analysis, or interpretation of data:
Markmann, Abouljoud, Ghobrial, Bhati, Pelletier, Lu,
Ottmann, Klair, Eymard, Roll, Pruett, Reyes, Black,
Marsh, Schnickel, Kinkhabwala, Florman, Merani,
Demetris, Kimura, Rizzari, Saharia, Levy, Cigarroa,
Eason, Syed, Washburn, Parekh, Yeh, Vagefi,
MacConmara.
Drafting of the manuscript: Markmann, Abouljoud,
Bhati, Kimura, Cigarroa, Parekh, MacConmara.
Critical revision of the manuscript for important
intellectual content: Abouljoud, Ghobrial, Bhati,
Pelletier, Lu, Ottmann, Klair, Eymard, Roll,
Magliocca, Pruett, Reyes, Black, Marsh, Schnickel,
Kinkhabwala, Florman, Merani, Demetris, Rizzari,
Saharia, Levy, Agarwal, Eason, Syed, Washburn,
Parekh, Moon, Maskin, Yeh, Vagefi, MacConmara.
Statistical analysis: Pruett, Saharia, Agarwal,
MacConmara.
Administrative, technical, or material support:
Ghobrial, Bhati, Pelletier, Lu, Eymard, Roll,
Magliocca, Schnickel, Kimura, Rizzari, Saharia, Levy,
Syed, Parekh, Moon, Vagefi, MacConmara.

Original Investigation Research

for transplant. The advent of portable, extracorporeal, donor
liver machine perfusion offers for the first time a convenient
and effective approach to both assess and enhance donor liver
function, thereby improving transplant safety, expanding the
liver donor pool, and reducing waiting list mortality.

Supervision: Markmann, Ghobrial, Klair, Eymard,
Roll, Black, Merani, Kimura, MacConmara.
Conflict of Interest Disclosures: Dr Bhati reported
receiving personal fees from Intuitive Surgical
outside the submitted work. Dr Pelletier reported
receiving funding from Organ Recovery Systems
outside the submitted work. Dr Lu reported
receiving nonfinancial support from Tampa General
Hospital during the conduct of the study. Dr Saharia
reported receiving nonfinancial support from
Houston Methodist Hospital during the conduct of
the study. Dr Cigarroa reported receiving financial
compensation from the Ford Foundation, Capital
Group, Kleberg Foundation, and Clayton
Foundation for Biomedical Research outside the
submitted work. Dr MacConmara reported
becoming employed by TransMedics after
completion of the OCS Liver PROTECT randomized
clinical trial and submission of the final manuscript.
No other disclosures were reported.
Funding/Support: This study was supported by
TranMedics Inc.
Role of the Funder/Sponsor: TranMedics led the
design of the trial protocol in collaboration with
senior investigators; was responsible for data
collection and generating the final study report;
assisted the authors in drafting and reviewing
figures, tables, and corresponding descriptions;
provided manuscript text suggestions to ensure
accuracy of the data presented; and at the request
of the authors, provided additional analyses of the
trial data to help address study investigator
questions. TranMedics Inc had no role in the clinical
interpretation of the data or the decision to submit
the manuscript for publication.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We thank our surgical
colleagues and study coordinators from all
participating centers for their efforts to successfully
complete this trial. David Cronin, MD, PhD,
University of Chicago, Chicago, Illinois, and Kareem
Abu Elmagd, MD, PhD, Cleveland Clinic, Weston,
Florida, supported this study in their roles as
chairman of the clinical events committee and the
chairman of the data and safety monitoring board,
respectively. Ahmed Elbetanony, MB, BCh,
TransMedics, Andover, Massachusetts, supported
the trial centers during enrollment. No one received
financial compensation for the stated contribution.
REFERENCES
1. Kwong A, Kim WR, Lake JR, et al. OPTN/SRTR
2018 annual data report: liver. Am J Transplant.
2020;20(suppl s1):193-299. doi:10.1111/ajt.15674
2. Klassen DK, Edwards LB, Stewart DE, Glazier AK,
Orlowski JP, Berg CL. The OPTN deceased donor
potential study: implications for policy and practice.
Am J Transplant. 2016;16(6):1707-1714. doi:10.1111/
ajt.13731
3. Feng S. Donor intervention and organ
preservation: where is the science and what are the
obstacles? Am J Transplant. 2010;10(5):1155-1162.
doi:10.1111/j.1600-6143.2010.03100.x

jamasurgery.com

Downloaded From: https://jamanetwork.com/ by a Henry Ford Health System User on 02/17/2022

4. Maathuis MH, Leuvenink HG, Ploeg RJ.
Perspectives in organ preservation. Transplantation.
2007;83(10):1289-1298. doi:10.1097/01.tp.
0000265586.66475.cc
5. Clavien PA, Harvey PR, Strasberg SM.
Preservation and reperfusion injuries in liver
allografts: an overview and synthesis of current
studies. Transplantation. 1992;53(5):957-978.
doi:10.1097/00007890-199205000-00001
6. Feng S, Goodrich NP, Bragg-Gresham JL, et al.
Characteristics associated with liver graft failure:
the concept of a donor risk index. Am J Transplant.
2006;6(4):783-790. doi:10.1111/j.1600-6143.2006.
01242.x
7. Trapero-Marugán M, Little EC, Berenguer M.
Stretching the boundaries for liver transplant in the
21st century. Lancet Gastroenterol Hepatol. 2018;3
(11):803-811. doi:10.1016/S2468-1253(18)30213-9
8. Zhai Y, Petrowsky H, Hong JC, Busuttil RW,
Kupiec-Weglinski JW. Ischaemia-reperfusion injury
in liver transplantation—from bench to bedside.
Nat Rev Gastroenterol Hepatol. 2013;10(2):79-89.
doi:10.1038/nrgastro.2012.225
9. Steinbrook R. Organ donation after cardiac
death. N Engl J Med. 2007;357(3):209-213. doi:10.
1056/NEJMp078066
10. Olthoff KM, Kulik L, Samstein B, et al. Validation
of a current definition of early allograft dysfunction
in liver transplant recipients and analysis of risk
factors. Liver Transpl. 2010;16(8):943-949. doi:10.
1002/lt.22091
11. Schön MR, Kollmar O, Wolf S, et al. Liver
transplantation after organ preservation with
normothermic extracorporeal perfusion. Ann Surg.
2001;233(1):114-123. doi:10.1097/00000658200101000-00017
12. St Peter SD, Imber CJ, Friend PJ. Liver and
kidney preservation by perfusion. Lancet. 2002;
359(9306):604-613. doi:10.1016/S0140-6736(02)
07749-8
13. Butler AJ, Rees MA, Wight DG, et al. Successful
extracorporeal porcine liver perfusion for 72 hr.
Transplantation. 2002;73(8):1212-1218. doi:10.1097/
00007890-200204270-00005
14. Liu Q, Nassar A, Farias K, et al. Sanguineous
normothermic machine perfusion improves
hemodynamics and biliary epithelial regeneration in
donation after cardiac death porcine livers. Liver
Transpl. 2014;20(8):987-999. doi:10.1002/lt.23906
15. Nassar A, Liu Q, Farias K, et al. Ex vivo
normothermic machine perfusion is safe, simple,
and reliable: results from a large animal model. Surg
Innov. 2015;22(1):61-69. doi:10.1177/
1553350614528383
16. Nasralla D, Coussios CC, Mergental H, et al;
Consortium for Organ Preservation in Europe.
A randomized trial of normothermic preservation in
liver transplantation. Nature. 2018;557(7703):50-56.
doi:10.1038/s41586-018-0047-9
17. Ali JM, Davies SE, Brais RJ, et al. Analysis of
ischemia/reperfusion injury in time-zero biopsies

(Reprinted) JAMA Surgery Published online January 5, 2022

E9

Research Original Investigation

predicts liver allograft outcomes. Liver Transpl.
2015;21(4):487-499. doi:10.1002/lt.24072
18. Kakizoe S, Yanaga K, Starzl TE, Demetris AJ.
Evaluation of protocol before transplantation and
after reperfusion biopsies from human orthotopic
liver allografts: considerations of preservation and
early immunological injury. Hepatology. 1990;11(6):
932-941. doi:10.1002/hep.1840110605
19. Sosa RA, Zarrinpar A, Rossetti M, et al. Early
cytokine signatures of ischemia/reperfusion injury
in human orthotopic liver transplantation. JCI Insight.
2016;1(20):e89679. doi:10.1172/jci.insight.89679
20. Sayed E, Selman E, El Khola A, Khalil M,
Lofty M. Intraoperative serum lactate concentration
and central venous oxygen saturation as early
predictors for early graft function during liver
transplant. J Anest Inten Care Med. 2018;5(1):555655.
doi:10.19080/JAICM.2018.05.555655
21. Ardehali A, Esmailian F, Deng M, et al; PROCEED II
trial investigators. Ex-vivo perfusion of donor hearts
for human heart transplantation (PROCEED II):
a prospective, open-label, multicentre, randomised
non-inferiority trial. Lancet. 2015;385(9987):
2577-2584. doi:10.1016/S0140-6736(15)60261-6
22. He X, Guo Z, Zhao Q, et al. The first case of
ischemia-free organ transplantation in humans:
a proof of concept. Am J Transplant. 2018;18(3):
737-744. doi:10.1111/ajt.14583
23. He X, Chen G, Zhu Z, et al. The first case of
ischemia-free kidney transplantation in humans.
Front Med (Lausanne). 2019;6:276. doi:10.3389/
fmed.2019.00276

E10

Impact of Portable Normothermic Blood-Based Machine Perfusion on Outcomes of Liver Transplant

24. Warnecke G, Moradiellos J, Tudorache I, et al.
Normothermic perfusion of donor lungs for
preservation and assessment with the Organ Care
System Lung before bilateral transplantation: a pilot
study of 12 patients. Lancet. 2012;380(9856):
1851-1858. doi:10.1016/S0140-6736(12)61344-0
25. Warnecke G, Van Raemdonck D, Smith MA,
et al. Normothermic ex-vivo preservation with the
portable Organ Care System Lung device for
bilateral lung transplantation (INSPIRE):
a randomised, open-label, non-inferiority, phase 3
study. [published correction appears in Lancet
Respir Med. 2018;6(6):e27]. Lancet Respir Med.
2018;6(5):357-367. doi:10.1016/S2213-2600(18)
30136-X
26. Loor G, Warnecke G, Villavicencio MA, et al.
Portable normothermic ex-vivo lung perfusion,
ventilation, and functional assessment with the
Organ Care System on donor lung use for
transplantation from extended-criteria donors
(EXPAND): a single-arm, pivotal trial. Lancet Respir
Med. 2019;7(11):975-984. doi:10.1016/S22132600(19)30200-0
27. Fondevila C, Hessheimer AJ, Maathuis MH,
et al. Superior preservation of DCD livers with
continuous normothermic perfusion. Ann Surg.
2011;254(6):1000-1007. doi:10.1097/SLA.
0b013e31822b8b2f

2015;262(5):764-770. doi:10.1097/SLA.
0000000000001473
29. Oniscu GC, Randle LV, Muiesan P, et al. In situ
normothermic regional perfusion for controlled
donation after circulatory death—the United
Kingdom experience. Am J Transplant. 2014;14(12):
2846-2854. doi:10.1111/ajt.12927
30. Mergental H, Laing RW, Kirkham AJ, et al.
Transplantation of discarded livers following
viability testing with normothermic machine
perfusion. Nat Commun. 2020;11(1):2939. doi:10.
1038/s41467-020-16251-3
31. van Rijn R, Schurink IJ, de Vries Y, et al;
DHOPE-DCD Trial Investigators. Hypothermic
machine perfusion in liver transplantation—a
randomized trial. N Engl J Med. 2021;384(15):
1391-1401. doi:10.1056/NEJMoa2031532
32. Williams WW, Markmann JF. Warming up to
cold perfusion. N Engl J Med. 2021;384(15):
1458-1459. doi:10.1056/NEJMe2102056
33. Snyder JJ, Salkowski N, Wey A, Pyke J,
Israni AK, Kasiske BL. Organ distribution without
geographic boundaries: a possible framework for
organ allocation. Am J Transplant. 2018;18(11):
2635-2640. doi:10.1111/ajt.15115

28. Dutkowski P, Polak WG, Muiesan P, et al. First
comparison of hypothermic oxygenated perfusion
versus static cold storage of human donation after
cardiac death liver transplants: an
international-matched case analysis. Ann Surg.

JAMA Surgery Published online January 5, 2022 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Henry Ford Health System User on 02/17/2022

jamasurgery.com

